Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma - Full Text View

Sponsors and Collaborators:	AIDS Associated Malignancies Clinical Trials Consortium National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00006264

Purpose

RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma.

PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma.

Condition	Intervention	Phase
Lymphoma	Biological: aldesleukin Drug: ganciclovir Drug: zidovudine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma

Resource links provided by NLM:

MedlinePlus related topics: AIDS Cancer Lymphoma

Drug Information available for: Zidovudine Ganciclovir Interleukin-2 Ganciclovir sodium Aldesleukin

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

July 2000

Detailed Description:

OBJECTIVES:

Determine the safety and toxicity of zidovudine, interleukin-2, and ganciclovir in patients with AIDS related primary central nervous system lymphoma.
Determine the response rate and overall survival of these patients treated with this regimen.

OUTLINE: This is a multicenter study.

Induction therapy: Patients receive zidovudine (AZT) IV and ganciclovir IV over 1 hour every 12 hours on days 1-14. Patients also receive interleukin-2 (IL-2) IV every 12 hours on days 1-14 and a combination antiretroviral therapy consisting of nucleoside reverse transcriptase inhibitors (one of which must be AZT), nonnucleoside reverse transcriptase inhibitors, and protease inhibitors. AZT and ganciclovir treatment continues for an additional 7 days if partial response is achieved.
Maintenance therapy: Patients receive IL-2 subcutaneously 3 times a week for 6 months. Patients also receive oral ganciclovir 3 times a day and combination antiretroviral therapy (AZT allowed, but not required). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for 1 year, every 3 months for 2 years, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 10-30 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

HIV positive
Diagnosis of central nervous system lymphoma by one of the following means:
- Brain biopsy
- Thallium spectroscopy scan in conjunction with CT scan or MRI after failing to improve with at least 2 weeks of antitoxoplasmosis therapy
- Cerebral spinal fluid positive for Epstein Barr virus in conjunction with positive thallium spectroscopy scan
- Thallium spectroscopy scan demonstrating a thallium retention index greater than 1
Documented intracranial space occupying lesion
No systemic non-Hodgkin's lymphoma

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Absolute granulocyte count at least 1,000/mm3
Platelet count at least 50,000/mm3

Hepatic:

Bilirubin and SGOT no greater than 3 times upper limit of normal
No major hepatic dysfunction as evidenced by encephalopathy, ascites, or varices

Renal:

Creatinine clearance at least 60 mL/min

Other:

No prior other malignancy within the past 5 years except carcinoma in situ of the cervix, basal cell carcinoma of the skin, or Kaposi's sarcoma not requiring systemic therapy
No active uncontrolled infection except HIV or Epstein Barr virus
No known allergy to E. coli derived products
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Concurrent corticosteroids allowed

Radiotherapy:

Not specified

Surgery:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006264

Locations

United States, Florida
Sylvester Cancer Center, University of Miami
Miami, Florida, United States, 33136
United States, Ohio
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States, 43210

Sponsors and Collaborators

AIDS Associated Malignancies Clinical Trials Consortium

National Cancer Institute (NCI)

Investigators

Study Chair:

William J. Harrington, MD

University of Miami Sylvester Comprehensive Cancer Center - Miami

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr; AIDS Associated Malignancies Clinical Trials Consortium. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma. 2006 Mar;6(5):399-402.

Study ID Numbers:	CDR0000068204, AMC-019
Study First Received:	September 11, 2000
Last Updated:	February 6, 2009
ClinicalTrials.gov Identifier:	NCT00006264 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

AIDS-related primary CNS lymphoma

Study placed in the following topic categories:

Antimetabolites
Anti-HIV Agents
Immunoproliferative Disorders
Acquired Immunodeficiency Syndrome
Central Nervous System Lymphoma, Primary
Zidovudine
Ganciclovir
Antiviral Agents
Reverse Transcriptase Inhibitors
Lymphatic Diseases

Aldesleukin
Anti-Retroviral Agents
HIV Seropositivity
Analgesics, Non-Narcotic
HIV Infections
Interleukin-2
Peripheral Nervous System Agents
Analgesics
Lymphoproliferative Disorders
Lymphoma

Additional relevant MeSH terms:

Antimetabolites
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Zidovudine
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Sensory System Agents
Therapeutic Uses
Analgesics
Lymphoma
Nucleic Acid Synthesis Inhibitors
Anti-HIV Agents
Immunoproliferative Disorders

Neoplasms by Histologic Type
Immune System Diseases
Enzyme Inhibitors
Ganciclovir
Antiviral Agents
Pharmacologic Actions
Lymphatic Diseases
Neoplasms
Aldesleukin
Interleukin-2
Analgesics, Non-Narcotic
Peripheral Nervous System Agents
Lymphoproliferative Disorders
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009